BUZZ-Moderna shares extend losses as analysts question valuations after cancer vaccine data
路透社2026/10/23 10:36October 23 - ** Shares of pharmaceutical company Moderna MRNA.O fell 4.7% in pre-market trading to $193.02, extending Thursday’s decline
** The stock closed down 17.57% on Thursday at $202.63, wiping out about $17.2 billion in market value after months of gains
** Earlier, the results of a late-stage melanoma clinical trial were inadvertently released on an oncology website, prompting the company and its partner Merck MRK.N to publish the full details of the trial (link)
** Data showed that, compared to using Keytruda alone, the experimental vaccine intismeran combined with Keytruda reduced the risk of death or recurrence from melanoma by 42%, and lowered the risk of cancer spreading by 38%
** Several Wall Street analysts said ahead of the meeting that investors were hoping the combination therapy would lower the risk of recurrence by 40% or more
** RBC analyst Luca Issi called the data “clearly impressive,” but noted the benefit was numerically lower than interim results, adding that despite the share price pullback, it is still “difficult to justify the company’s $81 billion valuation”
** Morningstar analysts said, “The share price rose too much after the initial results in August”
** As of Thursday’s close, MRNA had risen 587% so far this year, mainly due to the surge after the August preliminary results; the day before that announcement, the stock traded around $63
(To assist non-native English speakers, Reuters has automated the translation of its report into several other languages. Because automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated text and provides it solely for the convenience of readers. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SK Hynix abandons Solidigm US IPO plan; analysts say future NAND supply will decrease, benefiting Micron and SanDisk
The analyst team at LYNX Equity Strategies pointed out that if Solidigm's IPO funds had been used to expand NAND capacity in the US, it could have increased global supply after three years or more, thereby putting downward pressure on pricing. Now that this financing channel is closed, the associated risk has disappeared, which is a substantial positive for both Micron and SanDisk; however, for Intel, it is a minor negative, as it means losing a potential manufacturing project.
Western Digital CFO Refutes Claims of Peaking AI Demand: No Signs of Slowdown, Cooling Off Would Actually Help Us Catch Up with Demand Gap
Western Digital's CFO strongly supports AI storage demand, stating that hyperscale cloud providers are continuously expanding capital expenditures and are already discussing supply needs for 2030 to 2031. Although the company’s quarterly results exceeded expectations and profit guidance was raised, capital expenditures more than doubled compared to the same period last year, putting pressure on free cash flow. This has raised concerns in the market about the sustainability of investment returns in AI data centers, causing the stock to close down by about 3% on Friday.
Executives reveal new monetization strategy for Meta AI: Muse is ad-free but charges for enterprise services, and takes a commission on shopping through AI agents
Meta AI chief Alexandr Wang stated that Muse is available to regular users for free and that Meta has no plans to introduce advertisements. Meta plans to offer paid services to enterprises, but specific pricing and launch timeline have not been disclosed. He also mentioned that Meta's proprietary infrastructure, security systems, and data centers provide Muse with a competitive advantage that is difficult for rivals to replicate.
Crypto prices
More
